The roles of inactivated vaccines in older patients with infection of Delta variant in Nanjing, China.

BACKGROUND

The coronavirus disease 2019 (COVID-19) is spreading around the world. The COVID-19 vaccines may improve concerns about the pandemic. However, the roles of inactivated vaccines in older patients (aged ≥60 years) with infection of Delta variant were less studied.

METHODS

We classified the older patients with infection of Delta variant into three groups based on the vaccination status: no vaccination (group A, = 113), one dose of vaccination (group B, = 46), and two doses of vaccination (group C, = 22). Two inactivated COVID-19 vaccines (BBIBP-CorV or CoronaVac) were evaluated in this study. The demographic data, laboratory parameters, and clinical severity were recorded.

RESULTS

A total of 181 older patients with infection of Delta variant were enrolled. 111 (61.3%) patients had one or more co-morbidities. The days of "turn negative" and hospital stay in Group C were lower than those in the other groups ( < 0.05). The incidences of multiple organ dysfunction syndrome (MODS), septic shock, acute respiratory distress syndrome (ARDS), acute kidney injury, and cardiac injury in Group A were higher than those in the other groups ( < 0.05). The MV-free days and ICU-free days during 28 days in Group A were also lower than those in the other groups ( < 0.05). In patients with co-morbidities, vaccinated cases had lower incidences of MODS ( = 0.015), septic shock ( = 0.015), and ARDS ( = 0.008).

CONCLUSIONS

The inactivated COVID-19 vaccines were effective in improving the clinical severity of older patients with infection of Delta variant.